Related Experiment Video
Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Disseminated strongyloidiasis complicating glioblastoma therapy: a case report
Dawit Aregawi1, David Lopez, Mark Wick
1Neuro-Oncology Center and Departments of Neurology, Neurological Surgery, and Medicine (Hematology-Oncology), University of Virginia, Charlottesville, VA 22908-0432, USA.
Abstract:
Strongyloides stercoralis is an intestinal parasite that can cause fatal opportunistic infections in immunocompromised patients. Here we report an immunocompromised patient with glioblastoma who developed disseminated strongyloidiasis 6 weeks after completion of standard radiotherapy and concurrent temozolomide chemotherapy. She was effectively treated with albendazole and ivermectin. Strongyloidiasis should be considered in patients being treated for glioma who have lived or traveled to high risk areas and developed gram negative sepsis, along with gastrointestinal or respiratory symptoms, skin rash or SIADH.

